Previous screening results important for decision about smear tests after age 60

October 25, 2017, Karolinska Institutet

Being screened again after the age of 60 reduces the risk of cervical cancer in women who have previously had abnormal smear tests and in women who did not have smear tests in their 50s, researchers at Karolinska Institutet show. The study, which is published in PLOS Medicine, is important for setting guidelines on the age at which screening can be discontinued.

Despite being screened with gynaecological smear tests, relatively many over the age of 60 develop cervical cancer. There is currently a discussion on when and against what criteria screening should be discontinued. Different countries discontinue screening at different ages, and in Sweden the upper age limit was raised recently to 64.

Researchers at Karolinska Institutet have conducted a national study of over half a million women born between 1919 and 1945 in order to examine the incidence of cervical cancer in the over-60s. The researchers looked at the risk of developing cervical cancer between the ages of 61 and 80 depending on the women's screening history when in their 50s, and compared the risk of developing cervical cancer depending on if the women had been screened after the age of 60 or not.

Their results show that five in one thousand women over 60 who had not been screened in their 50s developed ; however, if the women were screened between 61 and 65, the risk dropped by 58 per cent to 3.3 cancers per thousand women. For women who previously had abnormal smear tests in their 50s, the reduction in risk associated with screening between the ages of 61 and 65 was also statistically significant.

"It might be a good idea to pay closer attention to the results of women's previous screenings when deciding at which age it can be discontinued," says Professor Pär Sparén at Karolinska Institutet's Department of Medical Epidemiology and Biostatistics who led the study.

The women who had only had normal smear tests in their 50s showed no measurable lower cancer risk with new tests after age 60. However, the researchers did observe fewer cases of advanced in 61 to 65-year-old women, since screening revealed the cancers at an earlier stage of development.

Explore further: Screening, HPV vaccine can prevent cervical cancer: FDA

More information: Jiangrong Wang et al. Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden, PLOS Medicine (2017). DOI: 10.1371/journal.pmed.1002414

Related Stories

Screening, HPV vaccine can prevent cervical cancer: FDA

February 8, 2017
(HealthDay)—Women can reduce their risk of cervical cancer through vaccination and screening, the U.S. Food and Drug Administration says.

Women should continue cervical cancer screening as they approach age 65

May 1, 2017
Cervical cancer is often thought of as a disease that primarily affects young women. Because of this, many older women fail to keep up with appropriate screening as they age. While current guidelines indicate that screening ...

Screening helps prevent cervical cancer in older women

January 14, 2014
New research from Queen Mary University of London reveals women over the age of 50 who don't attend cervical screening are four times more likely to be diagnosed with cervical cancer in later life.

More than a quarter of women missing smear tests are unaware they exist

July 3, 2017
More than a quarter (28 per cent) of women who are overdue for a smear test don't know about the cervical screening programme, according to a Cancer Research UK survey published in the July Edition of the European Journal ...

Regular smear tests boost chances of cure from 66 percent to 92 percent

March 2, 2012
Women can boost their chances of surviving cervical cancer substantially through regular cervical screening, claims a research paper published today in the British Medical Journal.

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.